Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Synopsis

Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel

Michal Solomon, Nadav Sahar, Felix Pavlotzky, Aviv Barzilai, Charles L. Jaffe, Abedelmajeed Nasereddin, and Eli SchwartzComments to Author 
Author affiliations: Sheba Medical Center, Tel Aviv, Israel (M. Solomon, N. Sahar, F. Pavlotzky, A. Barzilai, E. Schwartz); Hebrew University–Hadassah Medical School, Jerusalem, Israel (C.L. Jaffe, A. Nasereddin)

Main Article

Table 2

Epidemiologic, clinical, and therapy data of patients with mucosal leishmaniasis, Israel, 1993–2015*

Patient no.
 Age, y/ sex
 No. primary lesions
 Concurrent active CL
 Location of primary lesions
 Treatment
 ML symptoms
Primary cutaneous lesions
 Mucosal lesions
 After ML treatment failure
 Response
1
 28/M
 12
 No
 Trunk, upper extremities
 None
 IV SSG
 No failure
 CR
 Oral ulceration, nasal obstruction
2
 24/F
 1
 Yes
 Lower extremities
 Treated for concurrent CL
 IV SSG
 No failure
 CR
 Nasal obstruction
3
 28/M
 1
 No
 Lower extremities
 None
 IV L-AmB
 No failure
 CR
 Nasal obstruction
4
 28/M
 1
 No
 Neck
 IV SSG
 IV L-AmB
 No failure
 CR
 Nasal obstruction
5
 26/M
 1
 No
 Lower extremities
 IV SSG
 IV L-AmB
 No failure
 CR
 Nasal obstruction
6
 25/M
 1
 No
 Face
 IV SSG
 IV L-AmB
 No failure
 CR
 Oral ulceration
7
 41/M
 1
 Yes
 Lower extremities
 Treated for concurrent CL
 IV L-AmB
 IV SSG
 CL recurrence
 Nasal obstruction, lacrimal gland obstruction
8
 23/M
 4
 Yes
 Neck, lower extremities
 Treated for concurrent CL
 IV L-AmB
 No failure
 None
 Nasal obstruction, bone lesion
9
 31/M
 3
 No
 Upper and lower extremities
 None
 IV L-AmB
 No failure
 CR
 Nasal obstruction, rhinorrhea
10
 24/M
 1
 Yes
 Upper extremities
 Treated for concurrent CL
 IV L-AmB
 Miltefosine
 CR
 Nasal obstruction
11
 41/M
 0
 No
 No lesions†
 None
 Miltefosine
 No failure
 CR
 Oral ulceration
12
 25/M
 1
 NA
NA
 None
 IV SSG
 No failure
 CR
 NA
13
 22/M
 2
 No
 NA
 None
 IV SSG
 No failure
 CR
 Oral ulceration
14
 25/M
 3
 No
 Lower extremities
 None
 IV SSG
 No failure
 CR
 NA
15
 24/M
 7
 No
 Face, upper extremities
 None
 IV SSG
 No failure
 CR
 Oral ulceration, nasal obstruction
16
 28/M
 1
 No
 Upper extremities
 None
 IV L-AmB
 No failure
 CR
 Nasal obstruction
17 23/M 2 No Trunk None IV L-AmB Miltefosine CR Nasal obstruction

*CL, cutaneous leishmaniasis; CR, complete response; IV L-AmB, intravenous liposomal amphotericin B; IV SSG, intravenous sodium stibogluconate; ML, mucosal leishmaniasis; NA, not available.
†Patient 11 had no primary cutaneous lesion.

Main Article

Page created: March 17, 2019
Page updated: March 17, 2019
Page reviewed: March 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external